Dérivés hétérocycliques, leurs procédés de préparation,médicaments les contenant, utiles notamment comme inhibiteurs de l'aldose réductase
申请人:LABORATOIRES UPSA
公开号:EP0162776A2
公开(公告)日:1985-11-27
L'invention concerne de nouveaux composés de formule:
Inhibiteurs de l'aldose réductase. Traitement de certaines complications du diabète.
本发明涉及新的式化合物:
醛糖还原酶抑制剂。治疗糖尿病的某些并发症。
“Methylene Bridge” to 5-HT<sub>3</sub> Receptor Antagonists: Conformationally Constrained Phenylguanidines
作者:Ahmed S. Abdelkhalek、Genevieve S. Alley、Osama I. Alwassil、Shailesh Khatri、Philip D. Mosier、Heather L. Nyce、Michael M. White、Marvin K. Schulte、Małgorzata Dukat
DOI:10.1021/acschemneuro.8b00431
日期:2019.3.20
Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT3 receptor antagonists. We examined the structure activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT3 receptor antagonist.
PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C]QUINOLIZIN-3-ONES DERIVATIVES
申请人:Applied Research Systems ARS Holding N.V.
公开号:EP1102765A1
公开(公告)日:2001-05-30
US6723850B1
申请人:——
公开号:US6723850B1
公开(公告)日:2004-04-20
[EN] PROCESS FOR THE SYNTHESIS OF (1H)-BENZO[C]QUINOLIZIN-3-ONES DERIVATIVES<br/>[FR] PROCEDE DE SYNTHESE DE DERIVES DE (1H)-BENZO[C]QUINOLIZIN-3-ONES
申请人:APPLIED RESEARCH SYSTEMS
公开号:WO2000008019A1
公开(公告)日:2000-02-17
The present invention refers to a process for the preparation of (1H)-benzo[c]quinolizin-3-ones derivatives of general formula (I) which involves only three steps and the use, as starting products, of commercially available, or easily preparable, compounds. The compounds of formula (I) are useful as inhibitors of 5α-reductases.